Risk of Further Progression or Death Among Durable Progression-Free Survivors With Melanoma or Non-Small-Cell Lung Cancer in PD-1 Blockade Trials: Implications for Imaging Surveillance.
Lei DengChangchuan JiangKristopher AttwoodJoseph J ZhaoStuthi PerimbetiChen HuIgor PuzanovGrace K DyPublished in: JCO oncology practice (2023)
On the basis of their own risk tolerance level, our findings allow clinicians and dPFSors make data-driven decisions regarding the imaging surveillance schedule beyond every 3 months.